BVS — BIOVENTUS INC (Healthcare >> Medical Devices)
BVS FAQ
What is BVS's P/E ratio?
BIOVENTUS INC (BVS) currently trades at a P/E ratio of 21.88.
What is BVS's ROE?
BIOVENTUS INC reports a Return on Equity (ROE) of 15.08%.
What is BVS's dividend yield?
BIOVENTUS INC offers a dividend yield of 0.00%.
What is BVS's Deepscope Quality Score?
Deepscope rates BVS's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BVS?
Deepscope's AI Timing Score for BVS is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BVS belong to?
BIOVENTUS INC is classified under the Healthcare >> Medical Devices sector on the NASDAQ exchange.
|
USD 9.05
Price
-0.15
(-1.63%)
Day Change
|
|
|---|
BVS Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 46) và Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
ROA quá thấp so với ROE
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt lắm , ...
| Yếu tố Chất lượng |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
2058
|
| Magic Formula Rank by ROE |
2058
|
| Magic Formula Rank by ROIC |
1485
|
| Price | 9.05 |
| PBV / Sector |
2.66 / 7.47
|
| Earning Per Share | 0.41 |
| PE / Sector |
21.88 / 29.83
|
| PEG or PE/Growth / Sector |
-0.27 / 0.41
|
| Average 1M Daily Value |
6.32 M
|
| Average 1W Daily Value |
5.16 M
GREAT
|
| Yếu tố Kỹ thuật |
|
57% |
| Sức khỏe tài chính |
|
43% |
| Khả năng kiếm lợi nhuận |
|
56% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-11 09:55:13 |
| Symbol | BVS |
| Name | BIOVENTUS INC |
| Sector | Healthcare >> Medical Devices |
| Market | NASDAQ |
| Listed Shares | 67.75 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 623.28 / 18,663.85 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 4721 Emperor Boulevard, Durham, NC, United States, 27703
Phone: 919 474 6700
Website: https://www.bioventus.com
Employees: 940
Sector: Healthcare >> Medical Devices
Description: Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
Google